Beyond the GLP-1 Hype: Is Novo Nordisk's Diversified Pipeline Its Hidden Strength?
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.